Development of an Italian version of the Leicester cough questionnaire and its relationship with other symptom-specific measures for patients with chronic cough
-
Published:2024-06
Issue:
Volume:227
Page:107642
-
ISSN:0954-6111
-
Container-title:Respiratory Medicine
-
language:en
-
Short-container-title:Respiratory Medicine
Author:
Sorano Alessandra,
Fumagalli Carlo,
Cinelli EleniaORCID,
Birring Surinder S.ORCID,
Fontana Giovanni A.,
Lavorini FedericoORCID
Reference24 articles.
1. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis;Song;Eur. Respir. J.,2015
2. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial;Smith;Lancet Respir. Med.,2020
3. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study;Morice;Eur. Respir. J.,2021
4. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials;McGarvey;Lancet,2022
5. Efficacy and safety of gefapixant for refractory or unexplained chronic cough over 52 weeks;Birring;Am. J. Respir. Crit. Care Med.,2023